[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BE2011C041I2 - - Google Patents

Download PDF

Info

Publication number
BE2011C041I2
BE2011C041I2 BE2011C041C BE2011C041C BE2011C041I2 BE 2011C041 I2 BE2011C041 I2 BE 2011C041I2 BE 2011C041 C BE2011C041 C BE 2011C041C BE 2011C041 C BE2011C041 C BE 2011C041C BE 2011C041 I2 BE2011C041 I2 BE 2011C041I2
Authority
BE
Belgium
Application number
BE2011C041C
Other languages
French (fr)
Original Assignee
Bristol-Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co filed Critical Bristol-Myers Squibb Co
Publication of BE2011C041I2 publication Critical patent/BE2011C041I2/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE2011C041C 2000-05-26 2011-11-10 BE2011C041I2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (1)

Publication Number Publication Date
BE2011C041I2 true BE2011C041I2 (ja) 2020-08-20

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2011C041C BE2011C041I2 (ja) 2000-05-26 2011-11-10

Country Status (41)

Country Link
EP (3) EP1536234B1 (ja)
JP (1) JP4328525B2 (ja)
KR (2) KR100889887B1 (ja)
CN (2) CN1309735C (ja)
AR (1) AR031699A1 (ja)
AT (1) ATE271066T1 (ja)
AU (2) AU2001263466C1 (ja)
BE (1) BE2011C041I2 (ja)
BR (1) BRPI0111191B8 (ja)
CA (1) CA2409748C (ja)
CY (2) CY2011019I1 (ja)
CZ (1) CZ304451B6 (ja)
DE (2) DE60104282T2 (ja)
DK (1) DK1248802T3 (ja)
EC (1) ECSP024365A (ja)
EE (2) EE05557B1 (ja)
EG (1) EG24459A (ja)
ES (2) ES2571852T3 (ja)
FR (1) FR11C0053I2 (ja)
GE (1) GEP20053658B (ja)
HK (1) HK1048126B (ja)
HU (2) HU228137B1 (ja)
IL (1) IL152315A (ja)
LT (1) LT5133B (ja)
LU (1) LU91902I2 (ja)
LV (1) LV12994B (ja)
MX (1) MXPA02011534A (ja)
MY (1) MY136113A (ja)
NO (2) NO330797B1 (ja)
PE (1) PE20011338A1 (ja)
PL (1) PL206267B1 (ja)
PT (1) PT1248802E (ja)
RU (1) RU2283847C2 (ja)
SI (1) SI1248802T1 (ja)
SK (1) SK288131B6 (ja)
TR (1) TR200402703T4 (ja)
TW (2) TWI319405B (ja)
UA (1) UA87432C2 (ja)
UY (1) UY26723A1 (ja)
WO (1) WO2001092337A2 (ja)
ZA (1) ZA200208944B (ja)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SI1935427T1 (en) 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES
DE60225914T2 (de) 2001-05-23 2009-07-23 Bristol-Myers Squibb Co. Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen
AU2003243152A1 (en) * 2002-04-19 2003-11-03 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
TWI312368B (en) * 2002-12-23 2009-07-21 Bristol Myers Squibb Compan Mammalian cell culture processes for protein production
MXPA05006522A (es) * 2002-12-23 2006-02-17 Bristol Myers Squibb Co Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
PL378879A1 (pl) 2002-12-30 2006-05-29 Amgen Inc. Terapia skojarzona z czynnikami kostymulującymi
CA2543484C (en) 2003-10-27 2014-02-04 Amgen Inc. Modulation of immune response to an immunogen with ctla-4 and tnfbp
PT2253644E (pt) * 2005-12-20 2014-01-23 Bristol Myers Squibb Co Composições e métodos para a produção de uma composição
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
CA2832111A1 (en) 2006-12-20 2008-07-03 Mmrglobal, Inc. Antibodies and methods for making and using them
JP5298134B2 (ja) 2007-11-01 2013-09-25 パーシード セラピューティクス リミテッド ライアビリティ カンパニー 免疫抑制ポリペプチドおよび核酸
ES2657220T3 (es) 2008-10-02 2018-03-02 Aptevo Research And Development Llc Proteínas de unión multi-diana antagonistas de CD86
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
TW201134481A (en) * 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses
CN103534345A (zh) 2011-02-23 2014-01-22 安姆根有限公司 用于uvc暴射的细胞培养基及其相关方法
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
EP3207938B1 (en) 2012-05-11 2019-12-25 MedImmune Limited Ctla-4 variants
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
EP2866823A4 (en) * 2012-06-27 2016-03-02 Orban Biotech Llc CTLA4 FUSION PROTEINS FOR THE TREATMENT OF DIABETES
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
EA039141B1 (ru) 2014-01-13 2021-12-09 Эмджен Инк. Рекомбинантный белок с пониженным содержанием высокоманнозных гликоформ, способ его получения и применение
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
SI3926051T1 (sl) 2014-06-04 2024-06-28 Amgen Inc. Postopki zbiranja celičnih kultur sesalcev
SI3227454T1 (sl) 2014-12-01 2020-06-30 Amgen Inc. Postopek za manipuliranje ravni vsebnosti glikana glikoproteina
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
PL3283508T3 (pl) 2015-04-17 2021-10-11 Alpine Immune Sciences, Inc. Białka immunomodulacyjne o dostrajalnym powinowactwie
AU2016321298A1 (en) 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
CN109715210B (zh) * 2016-09-19 2023-05-30 昂科医药 Cd80和cd86结合蛋白组合物及其用途
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
JP2020517301A (ja) 2017-04-20 2020-06-18 イージェネシス，インコーポレイテッド 遺伝子改変動物の作成方法
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
CA3087149A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
EP4021479A2 (en) 2019-08-27 2022-07-06 Tonix Pharma Limited Modified tff2 polypeptides
SG11202110953UA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
MX2022016104A (es) 2020-06-18 2023-02-01 Regeneron Pharma Enfoque de peptidos pesados para medir con precision lisina de extremo c-terminal sin procesar.
WO2022027013A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
WO2023115027A2 (en) 2021-12-16 2023-06-22 Bristol-Myers Squibb Company Detergent for viral inactivation
JP2025507794A (ja) 2022-03-02 2025-03-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗体産生のためのバイオリアクター

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
WO1993000431A1 (en) * 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
AU1102000A (en) * 1998-10-07 2000-04-26 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
SI1935427T1 (en) * 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES

Also Published As

Publication number Publication date
BRPI0111191B8 (pt) 2021-05-25
CA2409748A1 (en) 2001-12-06
NO2011027I2 (ja) 2011-12-15
HK1048126B (en) 2005-03-04
AU6346601A (en) 2001-12-11
DE60104282T2 (de) 2005-10-13
PT1248802E (pt) 2004-11-30
EE201100050A (et) 2011-10-17
NO20025656D0 (no) 2002-11-25
SK15702002A3 (sk) 2004-01-08
EE05458B1 (et) 2011-08-15
HUP0302201A3 (en) 2010-01-28
UY26723A1 (es) 2001-12-28
EE200200659A (et) 2004-06-15
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
AU2001263466B2 (en) 2006-04-27
SK288131B6 (sk) 2013-10-02
WO2001092337A3 (en) 2002-05-10
TWI319405B (en) 2010-01-11
CY1117625T1 (el) 2017-04-26
LT2002114A (en) 2003-12-29
ES2571852T3 (es) 2016-05-27
ZA200208944B (en) 2004-02-13
ES2225549T3 (es) 2005-03-16
PL206267B1 (pl) 2010-07-30
AR031699A1 (es) 2003-10-01
CN101255192A (zh) 2008-09-03
CN1441810A (zh) 2003-09-10
JP4328525B2 (ja) 2009-09-09
UA87432C2 (uk) 2009-07-27
EP1536234A3 (en) 2009-06-03
KR100895134B1 (ko) 2009-05-04
KR100889887B1 (ko) 2009-03-24
MY136113A (en) 2008-08-29
CZ20023892A3 (cs) 2003-09-17
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
TWI314933B (en) 2009-09-21
EP3029062A1 (en) 2016-06-08
PE20011338A1 (es) 2002-01-13
EP1536234A2 (en) 2005-06-01
FR11C0053I1 (ja) 2012-01-13
ECSP024365A (es) 2003-03-31
IL152315A (en) 2010-04-15
CZ304451B6 (cs) 2014-05-14
BR0111191A (pt) 2004-07-06
JP2004511213A (ja) 2004-04-15
DE60104282D1 (de) 2004-08-19
PL366231A1 (en) 2005-01-24
FR11C0053I2 (fr) 2013-01-11
AU2001263466C1 (en) 2006-10-26
ATE271066T1 (de) 2004-07-15
LV12994B (en) 2003-08-20
CY2011019I1 (el) 2016-12-14
DE122011100063I1 (de) 2012-06-14
EG24459A (en) 2009-07-16
GEP20053658B (en) 2005-11-10
BRPI0111191B1 (pt) 2019-12-31
DK1248802T3 (da) 2004-11-15
IL152315A0 (en) 2003-05-29
NO330797B1 (no) 2011-07-18
NO20025656L (no) 2002-11-25
KR20030009502A (ko) 2003-01-29
EP1248802B1 (en) 2004-07-14
WO2001092337A2 (en) 2001-12-06
EE05557B1 (et) 2012-08-15
RU2283847C2 (ru) 2006-09-20
CN1309735C (zh) 2007-04-11
MXPA02011534A (es) 2004-08-12
NO2011027I1 (no) 2012-01-09
EP1536234B1 (en) 2016-03-16
CA2409748C (en) 2008-09-16
TR200402703T4 (tr) 2004-11-22
TW200906857A (en) 2009-02-16
HK1048126A1 (en) 2003-03-21
HU228137B1 (en) 2012-12-28
SI1248802T1 (en) 2005-02-28
EP1248802B9 (en) 2005-05-11
HK1071931A1 (en) 2005-08-05
LT5133B (lt) 2004-05-25
HUP0302201A2 (hu) 2003-10-28
HUS1300012I1 (hu) 2016-08-29

Similar Documents

Publication Publication Date Title
BE2016C018I2 (ja)
NO2011027I2 (ja)
BRPI0113420B8 (ja)
JP2003503097A5 (ja)
JP2000238274A5 (ja)
JP2002193110A5 (ja)
JP2003509678A5 (ja)
JP2002076352A5 (ja)
JP2001281583A5 (ja)
JP2001102926A5 (ja)
JP2001255510A5 (ja)
JP2002108290A5 (ja)
JP2002073220A5 (ja)
JP2001238443A5 (ja)
BRPI0003419A (ja)
JP2002143586A5 (ja)
IN191516B (ja)
ECSDI000166S (ja)
ECSDI000616S (ja)
CN3145095S (ja)
AU2001294354A8 (ja)
CN3145461S (ja)
CN3146291S (ja)
CN3144671S (ja)
CN3144584S (ja)